Based on this, PanTheryx - a biotechnology company headquartered in Colorado - through its nutritional intervention product has resolved a majority of cases involving pediatric diarrhoea after just one day of use, in its clinical trials.
PanTheryx flagship product, DiaResQ comprises immune factors, micronutrients and macronutrients that work with the body to address the underlying cause of diarrhoea.
No serious adverse events attributable to DiaResQ have been reported in its clinical trials that have collectively enrolled over 1,000 children and adults.
Supporting this, the company has announced the positive results of two new studies of DiaResQ at the ‘DiaResQ: A Scientific Update’ scientific symposium in Bangkok, Thailand recently.
In the first study, patients who received the standard of care plus DiaResQ showed a statistically significant improvement in the stool frequency, stool consistency and hydration status compared to standard of care alone.
Meanwhile in the second study, patients who consumed the product showed a significant improvement in the frequency of diarrhoea, improvement in stool consistency, shortened duration of illness and improved doctor reported well-being.
PanTheryx senior vice-president, Scott Hyman said it was vital the company continued to make progress in addressing diarrhoea, one of the leading causes of morbidity and mortality worldwide.
“We are working closely with clinicians and our partners to educate the medical community on the benefits of DiaResQ and ensure it is available to everyone, especially children who are most at risk.”
DiaResQ has been recognised as one of 30 leading healthcare innovations with great promise to transform global health by 2030 and help accelerate progress towards the United Nations Sustainable Development Goals health targets.
More details on https://diaresq.com/
-- BERNAMA
No comments:
Post a Comment